Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,521 across all filing types
Latest filing 2022-08-23 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - COMPLETION OF A CLINICAL STUDY OF HETEROLOGOUS BOOSTER IMMUNIZATION OF SARS-CoV-2 mRNA VACCINE (SYS6006)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the completion of a clinical study for a SARS-CoV-2 mRNA vaccine booster. It details the study design, safety, and immunogenicity results, and future plans for the vaccine. There is no indication that this is a full financial report, audit report, earnings release, or any regulatory filing related to financials. It is not a presentation, call transcript, or management report. The document is an announcement of clinical study results, which does not fit into financial or governance report categories. It is a voluntary announcement about a clinical study completion, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2022-08-23 English
VOLUNTARY ANNOUNCEMENT - SELECTIVE NTRK AND ROS1 DUAL INHIBITOR "SYHX2009" OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a short announcement from the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug product. It is labeled as a "Voluntary Announcement" and contains no financial data, no detailed report, or regulatory filing content. The length is only 2003 characters, which is quite short and typical for an announcement rather than a full report. There is no indication that this is an annual report, earnings release, or any other detailed financial or regulatory filing. It is not a report publication announcement since it does not mention any report being published or attached. The content is about a clinical trial approval, which is a regulatory or operational update but does not fit into categories like legal proceedings or management changes. Given the nature and length, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-08-22 English
VOLUNTARY ANNOUNCEMENT - CLASS 1 NEW DRUG "PRUSOGLIPTIN TABLETS" MEETS PREDEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIALS FOR THE TREATMENT OF TYPE 2 DIABETES
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the successful results of pivotal clinical trials for a new drug, Prusogliptin Tablets, for the treatment of type 2 diabetes. It discusses clinical trial outcomes, future regulatory submission plans, and market prospects. The document is relatively short (3813 characters) and is an announcement of clinical trial results rather than a detailed financial report, regulatory filing, or management discussion. It does not contain financial statements, voting results, or executive changes. It is not a report publication announcement since it contains substantive information about the clinical trial results and company plans. The content fits best under a general regulatory announcement category as it informs the market about significant clinical progress and future regulatory steps. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-08-22 English
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2022
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the half year ended 30 June 2022. It references the half-yearly report published by the subsidiary on the Shenzhen Stock Exchange website and provides detailed financial data such as revenue, net profit, cash flows, and changes in assets. The document includes multiple appendices with financial indicators, non-recurring gain/loss items, significant changes in asset components, and year-on-year changes in principal financial data. The content is comprehensive and contains substantive financial data for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report publication, nor is it a certification or a brief summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-19 English
VOLUNTARY ANNOUNCEMENT - "MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of a new product. It is a short announcement (2534 characters) and does not contain financial data, detailed financial performance, or regulatory certifications. It is not a report but an announcement of a significant event related to the company's product portfolio. There is no indication of it being a financial report, management discussion, or regulatory filing. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2022-08-19 English
VOLUNTARY ANNOUNCEMENT - DUOENDA (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a drug (Duoenda) for a specific medical condition. It is an announcement of a regulatory approval event and does not contain financial data, management discussion, or detailed report content. The document is relatively short (3789 characters) and serves as a public disclosure of a significant company event rather than a financial or management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications, but rather a voluntary announcement of a clinical trial approval. Given the filing definitions, this type of document best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.